£7M to drive commercialisation in cell and gene therapies (CGTs) 

Cell and gene therapy

MIP Discovery has closed a £7 million GBP (~$9 million USD) Series A financing round, which enables the company to refocus its mission on improving the downstream processing of cell and gene therapies (CGTs), to accelerate widespread adoption of these potentially life-changing medicines.   

MIP Discovery develops non-biological affinity reagents designed to accelerate the development and production of CGTs.  

The funding, led by Mercia Ventures along with existing investor Calculus Capital and other Angel investors, will be used to drive further commercialisation of MIP Discovery’s novel synthetic affinity reagents within the CGT space.  

The funds will also support recruitment efforts to expand in-house CGT expertise. MIP Discovery’s non-biological affinity reagents support a new approach to viral vector characterisation, viral vector purification, and safety and QC processes, such as the detection and removal of impurities. 

Technologies for viral vectors 

Viral vectors are a critical component for many CGTs, and yet many of the current technologies used to characterise, develop, and manufacture them do not meet the required standards for scale, performance, or economics.  

Mike Evans, Chair of MIP Discovery, said: “MIP Discovery’s synthetic affinity reagents offer an innovative alternative to antibodies, and are better suited for downstream processing of advanced therapies. Backed by our proven technology and the confidence of our investors, we hope to help increase the affordability of cell and gene therapies, enabling the efficient delivery of these potentially life-saving treatments on a global scale.” 

Dr Mark Payton, CEO of Mercia, said: “The broader CGT market is a rapidly growing multi-billion-dollar market and its next stage of evolution is to focus down on technologies that reduce the cost of production and purification to ensure this therapeutic benefit is available for the many. Using MIPs’ sophisticated and highly scalable synthetic chemistry approach means they are well positioned to benefit from this tremendous high growth opportunity.” 

Liz Klein, Investment Director at Calculus, added: “MIP Discovery’s synthetic affinity reagents hold huge potential to overcome bottlenecks in CGT development and production. We are delighted to be further backing MIP as they are making significant technical progress.” 

By MEGAN THOMAS, Multimedia Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free